<DOC>
	<DOCNO>NCT00039689</DOCNO>
	<brief_summary>There evidence early aggressive treatment antiretroviral drug prevent loss immune cell function accompany HIV infection . This study use leukapheresis ( draw blood , separate white cell return blood patient ) obtain blood cell HIV-infected patient either acute chronic stage infection treat early highly active antiretroviral therapy ( HAART ) . Leukapheresis necessary obtain enough cell delineate response B cell CD4+ T cell help , CD8 factor associate suppression viral replication normalization immune function , natural killer function relative HIV disease . Study participant adult ( old 18 year ) HIV primary acutely affected patient ( history exposure HIV yet show chronic symptom HIV disease ) HIV chronically infect patient ( infected HIV longer 12 month show symptom HIV disease ) receive HAART begin study . The study seek enroll 30 primary 30 chronic patient . Pregnant woman enrol study ; woman become pregnant drop study . Leukapheresis perform patient HAART therapy begin three time year . Each session take 1 3 hour . This longitudinal study enable researcher examine function certain B cell , natural killer cell , CD8+ T cell people chronic HIV disease disease treat HAART .</brief_summary>
	<brief_title>Leukapheresis Procedures Obtain Plasma Lymphocytes Research Studies Primary Chronic HIV-Infected Patients</brief_title>
	<detailed_description>HIV infection know cause profound irreversible dysfunction innate adaptive arm immune system . However , mount evidence early aggressive treatment antiretroviral drug prevent loss immune cell function . In attempt delineate effect early antiretroviral therapy ( ART ) maintenance immune cell function , wish recruit drug-na ( SqrRoot ) HIVinfected patient either early chronic stage infection . The study require patient undergo leukapheresis research blood draw several time enrollment . Leukapheresis use order obtain sufficient cell pursue follow objective : delineating B cell response CD4+ T cell help , delineate effect ART persistent HIV reservoirs CD4+ T cell infected individual , delineate CD8+ T cell-mediated suppression viral replication normalization immune function , characterize natural killer ( NK ) function relative HIV disease . The required number mononuclear cell need perform experiment easily safely obtain use leukapheresis procedure Clinical Center Apheresis Unit . This protocol specifically design conform requirement Apheresis Unit donor leukapheresis procedure , protocol , , independent research study . Alternatively , whole blood draw use case patient unable undergo leukapheresis . While approach limit extensive functional analysis , informative phenotypic limit functional analysis nonetheless perform .</detailed_description>
	<criteria>INCLUSION CRITERIA : Adult ( 18 year old old ) HIV1infected patient Adequate venous access apheresis sufficient research blood collection Positive HIV antibody immunoassay positive confirmatory HIV test define current CDC criterion . Tests may do clinic outside provider . For individual suspect early infection ; follow criterion may use : history exposure know source HIVinfected material individual clinical symptom sign consistent acute HIV infection ( fever , sore throat , malaise , maculopapular rash combine one following : positive HIV antibody immunoassay confirmatory HIV test define current CDC criterion ) ; positive HIV antibody immunoassay , negative confirmatory test subsequently evolve positive result ; HIV RNA level &gt; 2,000 copies/ml negative result HIV antibody immunoassay . Willingness able make follow visit least next 4 month prior initiation antiretroviral therapy . Blood pressure le 180/100 ; pulse rate 50100 unless low pulse reat consider normal volunteer Adequate blood count ( hemoglobin great equal 9.0 g/dL , hematocrit great equal 28 percent , platelet greaterhan equal 50,000 ) Willingness give inform consent include consent storage blood sample HLA test Antiretroviral naive antiretroviral use last six month EXCLUSION CRITERIA : Pregnant and/or breastfeed woman . Be currently acusing alcohol drug potentially could interfere patient compliance Have condition opinion investigator would make patient ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 24, 2017</verification_date>
	<keyword>Primary HIV Infection</keyword>
	<keyword>Chronic HIV Infection</keyword>
	<keyword>Antiretroviral Therapy</keyword>
	<keyword>Innate Immunity</keyword>
	<keyword>B Cell</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>Acute Infection</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>